TransMedics Group, Inc.
TMDX · Healthcare
$82.24
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offers legal representation for affected investors.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offering legal representation for affected investors.
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MVST
Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. The firm is seeking shareholders who currently own TMDX stock to join the investigation.